Canada markets open in 7 hours 58 minutes

Abeona Therapeutics Inc. (ABEO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2100+0.0100 (+0.83%)
At close: 4:00PM EDT

Abeona Therapeutics Inc.

1330 Avenue of the Americas
33rd Floor
New York, NY 10019
United States
646 813 4701
http://www.abeonatherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees76

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael AmorosoPres, CEO & Director571.92kN/A1978
Mr. Edward G. CarrSr. VP, CFO & Chief Accounting Officer437.4kN/A1969
Mr. Brian Kevany Ph.D.VP of Manufacturing & Interim Head of Quality and Technical OperationsN/AN/AN/A
Mr. Gregory GinVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Brendan M. O'MalleyCorp. Sec., VP and Head of Legal & IPN/AN/AN/A
Scott SantiamoDirector of Corp. CommunicationsN/AN/AN/A
Ms. Kristina MaximenkoVP of HRN/AN/AN/A
Dr. Vishwas Seshadri M.B.A., Ph.D.Sr. VP and Head of Research & Clinical Devel.N/AN/AN/A
Sofia WarnerSr. Director of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in New York, New York.

Corporate Governance

Abeona Therapeutics Inc.’s ISS Governance QualityScore as of July 1, 2021 is 9. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.